DEF 14A: BioXcel Therapeutics Seeks Stockholder Approval for Reverse Stock Split to Maintain Nasdaq Listing

BioXcel Therapeutics is asking stockholders to approve a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

Summary

• BioXcel Therapeutics is holding a special meeting on January 28, 2025, to vote on a proposal to authorize a reverse stock split of its common stock at a ratio between 1-for-5 and 1-for-30.
• The reverse stock split aims to increase the company's stock price to meet Nasdaq's continued listing requirements, specifically the minimum bid price of $1.00 per share.
• As of December 17, 2024, the company's stock price was $0.3901, and it had until March 17, 2025, to regain compliance.
• If the company fails to regain compliance by March 17, 2025, it may request an additional 180-day compliance period, potentially extending the deadline to September 13, 2025.
• The board believes the reverse stock split could improve the marketability and liquidity of the company's common stock.
• As of November 30, 2024, BioXcel Therapeutics had 48,348,364 shares of common stock issued and outstanding.
• The reverse stock split would reduce the number of outstanding shares to between approximately 1,611,612 and 9,669,672, depending on the ratio chosen by the board.
• The company's authorized share capital will remain at 200,000,000 shares.
• Stockholders will receive cash for fractional shares resulting from the reverse stock split, based on the market value of the stock on the last trading day before the effective date.
• The board has the discretion to abandon the reverse stock split if it determines it is not in the company's best interests.

Sentiment

Score: 5

Explanation: The document is neutral in tone, presenting the facts surrounding the proposed reverse stock split. While the need for a reverse stock split indicates underlying challenges, the document focuses on the procedural aspects and potential benefits of the proposal.

Positives

• The reverse stock split aims to maintain the company's listing on the Nasdaq Capital Market, which the board believes is in the best interest of the company and its stockholders.
• Maintaining the Nasdaq listing could improve the company's ability to raise additional funds and avoid lower prices and larger spreads in the bid and ask prices for the company's common stock.
• The increased market price of the common stock expected as a result of implementing the reverse stock split may improve marketability and liquidity of the common stock and may encourage trading.

Negatives

• Reverse stock splits can have a negative perception among some investors, analysts, and other stock market participants.
• The stock price of some companies that have effected reverse stock splits has subsequently declined, with a corresponding decline in market capitalization.
• The reverse stock split may increase the number of stockholders who own odd lots (less than 100 shares), which could increase the cost of selling their shares and may have greater difficulty in effecting sales.
• Some stockholders may cease being stockholders of the company following the reverse stock split.

Risks

• The market price of the company's common stock may not remain above $1.00 following the reverse stock split.
• Nasdaq may delist the company's common stock, which could harm the liquidity of the common stock and the company's ability to raise capital.
• A reverse stock split would increase the company's authorized but unissued shares of common stock, which could negatively impact a potential investor if they purchased shares of common stock.
• The issuance of additional shares of common stock or securities convertible into common stock may have a dilutive effect on earnings per share and relative voting power and may cause a decline in the trading price of the common stock.

Future Outlook

The company intends to request an additional 180-day extension from Nasdaq, if necessary, to regain compliance with the Minimum Bid Price Requirement. The Board will determine whether to implement the reverse stock split and the specific ratio based on market conditions and the best interests of the company.

Industry Context

Reverse stock splits are a relatively common strategy for companies facing delisting from exchanges due to low stock prices. Other companies in the biotechnology sector facing similar challenges may consider similar actions to maintain their listing status and access to capital markets.

Comparison to Industry Standards

• Many small-cap biotechnology companies with promising but pre-revenue pipelines face similar challenges in maintaining Nasdaq listing compliance.
• Comparable companies that have recently undertaken reverse stock splits to maintain compliance include [hypothetical company A] and [hypothetical company B].
• The success of a reverse stock split in maintaining compliance and improving stock performance varies widely and depends on the company's underlying fundamentals and market sentiment.

Stakeholder Impact

• The reverse stock split will impact stockholders by reducing the number of shares they own, although their percentage ownership will remain the same (except for fractional shares).
• The reverse stock split could affect the marketability and liquidity of the company's common stock, potentially impacting stockholders' ability to buy or sell shares.
• The reverse stock split aims to maintain the company's listing on the Nasdaq Capital Market, which could benefit stockholders by improving the company's access to capital and avoiding lower stock prices.

Next Steps

• Stockholders will vote on the reverse stock split proposal at the Special Meeting on January 28, 2025.
• The Board of Directors will determine the specific reverse stock split ratio, if approved.
• The company will file the Reverse Stock Split Certificate of Amendment with the Secretary of State of Delaware, if the reverse stock split is implemented.
• The company will notify stockholders regarding the exchange of stock certificates, if the reverse stock split is implemented.

Key Dates

Keywords

reverse stock split, Nasdaq, minimum bid price, listing requirements, common stock, BTAI, delisting, stockholders